openPR Logo
Press release

Leishmaniasis Treatment Market to Witness Robust Expansion Throughout the Forecast Period 2018-2026 Appraised By Global Players Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited

02-21-2019 01:47 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Global Leishmaniasis Treatment Market

Global Leishmaniasis Treatment Market

Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted through the bite of infected female phlebotomine sand flies. According to the World Health Organization (WHO), approximately 7, 00,000 to 1 million new cases and 20,000 - 30,000 deaths occur worldwide annually due to the leishmaniasis. There are three forms of leishmaniasis namely mucocutaneous leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis. Visceral leishmaniasis (VL) is the most serious condition among the other two forms of leishmaniasis. According to the World Health Organization (WHO), about 50,000 to 90,000 new cases of visceral leishmaniasis occur worldwide annually. According to the WHO, in 2015, more than 90% of the new cases of visceral leishmaniasis were from Kenya, Somalia, Ethiopia, India, Brazil, Sudan, and South Sudan creating higher opportunity for leishmaniasis treatment market.

For In depth Information Get Sample Copy of this Report at: https://www.coherentmarketinsights.com/insight/request-sample/932

The prevalence of cutaneous leishmaniasis in the North and South America, the Middle East, Central Asia, and Mediterranean basin is approximately 95%, according to the WHO April 2017 factsheet. People with leishmaniasis infection develop several symptoms, such as fever, weight loss, sores on skin, nose, mouth or throat, enlargement of spleen and liver, and abnormal blood tests. Some patients show symptoms of anemia, leukopenia, and thrombocytopenia. Geriatric population, infants, pregnant or lactating women, and HIV infected people have a high risk of acquiring leishmaniasis infections, due to their weak immune systems.

Leishmaniasis Disease Transmission Is Mostly Associated With Unhygienic Conditions, Weak Immune System, And Malnutrition. Increasing Climatic Changes And Population Mobility Are Other Risk Factors Associated With The Leishmaniasis Disease.

Depending on the degree of virulence and clinical preferences, the disease is characterized on the basis of the type of species and subspecies of leishmania parasite. The clinical pattern of disease, the geographic regions, and the immunological status of the patient are considered in leishmaniasis treatment. Multiple medical treatment options are available for treatment of cutaneous leishmaniasis, which includes parenteral and oral medications, infiltration of sodium stibogluconate at 0.3-0.8 ml, cryotherapy, local heat therapy at 40-420C, and topical paromomycin preparations. Leishmaniasis can be prevented by treating malnutrition, recurrent systemic infection or local infection. Tailored disease management for treating leishmaniasis is expected to have a potential for improving leishmaniasis treatment market in near future.

Leishmaniasis Treatment Market Taxonomy:

On the basis of disease type, the leishmaniasis treatment market is segmented into:
Cutaneous leishmaniasis
Visceral leishmaniasis
Mucocutaneous leishmaniasis

On the basis of drug type, the leishmaniasis treatment market is segmented into:
Pentavalent antimonials
Sodium stibogluconate
SSG Meglumine antimoniate
Antibiotics
Amphotericin B
Liposomal amphotericin B
Miltefosine
Paromomycin
Pentamidine

Introduction Of New Chemical Entity Will Drive The Leishmaniasis Treatment Market:

According to data published in 2017, by Drugs for Neglected Diseases initiative (DNDi’), two new chemical entities (NCE) DNDI-6148 and DNDI-0690 are introduced into the preclinical development stage to treat visceral and cutaneous leishmaniasis in 2016. Immunomodulator- CpG-D35, is also in pre-clinical development stage, which will be used as an adjunct along with drug therapy to fight cutaneous leishmaniasis. These advances have the potential to transform drug development into new treatment therapy in near future, in turn driving the growth of leishmaniasis treatment market.

Combined Agreement Between Who And Gilead Sciences, Inc. Will Expand Leishmaniasis Treatment Market:

In 2016, the World Health Organization (WHO) and Gilead Sciences, Inc. signed an agreement to donate 3,80,400 vials of AmBisome (liposomal amphotericin B), extending their previous agreement from 2016 to 2021. The five year collaboration and funding of US$ 20 million by Gilead Sciences, Inc. are intended to provide access to diagnosis and treatment to the populations affected by visceral leishmaniasis in key endemic countries such as Ethiopia, India, Nepal, Bangladesh, South Sudan, and Sudan. Financial contribution made by Gilead Sciences, Inc. helped WHO to expand, control, and reinforce surveillance in many endemic countries.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/932

Key Players In The Leishmaniasis Treatment Market:

Key players operating in the leishmaniasis treatment market include Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited, and Lifecare Innovations Private Limited.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Leishmaniasis Treatment Market to Witness Robust Expansion Throughout the Forecast Period 2018-2026 Appraised By Global Players Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited here

News-ID: 1607400 • Views: 297

More Releases from Coherent Market Insights

Barcode Verifiers Market Growth by 2028 Involving Prominent Players Such as: Cog …
The "Barcode Verifiers Market" research report offers important information about the state of the sector. This research offers in-depth details on the industry's foundation, productivity, strengths, manufacturers, and current trends that support business expansion and economic strength. The study makes an effort to maintain a thorough analysis and offer a geographical overview of the worldwide Barcode Verifiers Market. The report covers key info about the industry, current and future market
Diamond Wire Wafer Slicing Machine Market to Witness Strong Growth by 2028 | Sam …
The "Diamond Wire Wafer Slicing Machine Market" research report offers important information about the state of the sector. This research offers in-depth details on the industry's foundation, productivity, strengths, manufacturers, and current trends that support business expansion and economic strength. The study makes an effort to maintain a thorough analysis and offer a geographical overview of the worldwide Diamond Wire Wafer Slicing Machine Market. The report covers key info about
Load Haul and Dump Trucks Market Global Demand Analysis & Opportunity Outlook 20 …
𝗧𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗟𝗼𝗮𝗱 𝗛𝗮𝘂𝗹 𝗮𝗻𝗱 𝗗𝘂𝗺𝗽 𝗧𝗿𝘂𝗰𝗸𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗶𝘀 𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝘁𝗼 𝗲𝘅𝗵𝗶𝗯𝗶𝘁 𝗮 𝗖𝗔𝗚𝗥 𝗼𝗳 𝟲.𝟱% 𝗶𝗻 𝘁𝗵𝗲 𝗳𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝗽𝗲𝗿𝗶𝗼𝗱 𝟮𝟬𝟭𝟴-𝟮𝟬𝟮𝟲 The "Load Haul and Dump Trucks Market" research report offers important information about the state of the sector. This research offers in-depth details on the industry's foundation, productivity, strengths, manufacturers, and current trends that support business expansion and economic strength. The study makes an effort to maintain a thorough analysis
MOSFET and IGBT Gate Drivers Market Future Scenario, Growth rate, Market Segment …
The "MOSFET and IGBT Gate Drivers Market" research report offers important information about the state of the sector. This research offers in-depth details on the industry's foundation, productivity, strengths, manufacturers, and current trends that support business expansion and economic strength. The study makes an effort to maintain a thorough analysis and offer a geographical overview of the worldwide MOSFET and IGBT Gate Drivers Market. The report covers key info about

All 5 Releases


More Releases for Leishmania

Leishmaniasis Treatment Market Expected to Raise at CAGR of 8.8% by 2019-2026 | …
According to the current analysis of Reports and Data, the global Leishmaniasis Treatment market was valued at USD 104.8 million in 2018 and is expected to reach USD 206.5 million by the year 2026, at a CAGR of 8.8%. A disease outbreak takes place when a disease escalates by a higher number than expected in a region or during a season. An outbreak may occur in one community or even
Leishmaniasis Treatment Market, By Disease Type, and Drug Type
Leishmaniasis is parasitic disease caused due to an infection with Leishmania parasites and transmitted through the bite of infected female phlebotomine sand flies. According to the World Health Organization (WHO), approximately 7, 00,000 to 1 million new cases and 20,000 - 30,000 deaths occur worldwide annually due to the leishmaniasis. There are three forms of leishmaniasis namely mucocutaneous leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis. Visceral leishmaniasis (VL) is the most
Leishmaniasis Treatment Market Poised for Steady Growth in the Future
Leishmaniasis is a disease caused by the Leishmania parasites. The Leishmania parasite is a single cell protozoan, which is transmitted by the bite of the female phlebotomine sand fly infected by the parasite. There are over 20 Leishmania species reported, which are transmitted to humans by the bite of infected female phlebotomine sandflies. Furthermore, over 90 sand-fly species are known to transmit Leishmania parasites. Leishmaniasis consists of three different forms:
Market Research on Leishmaniasis Treatment Market 2017 and Analysis to 2025
Leishmaniasis is a disease caused by the Leishmania parasites. The Leishmania parasite is a single cell protozoan, which is transmitted by the bite of the female phlebotomine sand fly infected by the parasite. There are over 20 Leishmania species reported, which are transmitted to humans by the bite of infected female phlebotomine sandflies. Furthermore, over 90 sand-fly species are known to transmit Leishmania parasites. Leishmaniasis consists of three different forms:
Leishmaniasis Treatment Market - Industrial applications witness fastest growth …
Leishmaniasis is a disease caused by the Leishmania parasites. The Leishmania parasite is a single cell protozoan, which is transmitted by the bite of the female phlebotomine sand fly infected by the parasite. There are over 20 Leishmania species reported, which are transmitted to humans by the bite of infected female phlebotomine sandflies. Furthermore, over 90 sand-fly species are known to transmit Leishmania parasites. Leishmaniasis consists of three different forms:
Leishmaniasis Treatment Market Volume Forecast and Value Chain Analysis 2017-202 …
Leishmaniasis is a disease caused by the Leishmania parasites. The Leishmania parasite is a single cell protozoan, which is transmitted by the bite of the female phlebotomine sand fly infected by the parasite. There are over 20 Leishmania species reported, which are transmitted to humans by the bite of infected female phlebotomine sandflies. Furthermore, over 90 sand-fly species are known to transmit Leishmania parasites. Leishmaniasis consists of three different forms: visceral Leishmaniasis, cutaneous Leishmaniasis, and mucocutaneous